Oral News and Research

RSS

LX211 may become the first approved oral treatment for modifying the course of uveitis

An experimental drug, LX211 (LUVENIQ - oral voclosporin), may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions inevitably associated with either severe vision loss or substantial morbidity from steroid use.

27 Oct 2009

New data on KAPIDEX for nighttime heartburn in adults with non-erosive GERD presented at the 2009 ACG

New data being presented at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting in San Diego showed that treatment with KAPIDEX(TM) (dexlansoprazole) delayed release capsules over a four-week period resulted in a statistically significant greater percentage of nights without heartburn in subjects with non-erosive gastroesophageal reflux disease (GERD), compared to placebo (p<0.001).

27 Oct 2009

Issuance of patents for Idera Pharmaceuticals' TLR-targeted compounds announced

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the issuance of patents covering its novel Toll-like Receptor (TLR) - targeted compounds. The Company’s TLR-targeted compounds are based on synthetic DNA and RNA, which it refers to as immune modulatory oligonucleotides, or IMO®.

27 Oct 2009

Shire reports results of Lialda and 5-ASA persistency analyses

Shire plc, the global specialty biopharmaceutical company, presented the results of three 5-aminosalicylic acid (5-ASA) persistency analyses at ACG 2009 Annual Scientific Meeting, evaluating persistency of Lialda® (mesalamine), Asacol® (mesalamine), Pentasa® (mesalamine) (250mg and 500mg), balsalazide [combined results from generic balsalazide disodium and Colazal® (balsalazide disodium)], and Dipentum® (olsalazine sodium) (500mg).

27 Oct 2009

Protein crucial for insulin regulation may play a role in diabetes

A cellular protein from a family involved in several human diseases is crucial for the proper production and release of insulin, new research has found, suggesting that the protein might play a role in diabetes.

27 Oct 2009

TNF-alpha inhibitors and interleukin inhibitors to drive psoriasis drug market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of marketed and emerging TNF-alpha inhibitors and interleukin inhibitors will drive the psoriasis drug market to increase from $3 billion in 2008 to $5.2 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

27 Oct 2009

Oral contraceptives increase stroke risk but benefits still outweigh risks for most users

Nearly 100 million women worldwide use birth control pills. Pills now in use contain much lower concentrations of estrogens than older preparations. The relationship between oral contraceptives and stroke has been studied and debated for decades, and studies have yielded conflicting results.

27 Oct 2009

Inhibikase Therapeutics to illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases

Inhibikase Therapeutics, a specialty pharmaceutical company based in Atlanta, Georgia, will discuss simultaneous antiviral and antibacterial activity from small molecule agents at the 2009 BIOCOM Investor Conference. Employing a host-factor targeted approach, Inhibikase will illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases in humans.

27 Oct 2009

United Treatment Centers announces partnership with Quorum Productions

United Treatment Centers Inc. announced today the partnership with Quorum Productions, Inc., a wholly-owned operating subsidiary of O2 Media, Inc. O2 Media, Inc. is a production company that is nationally renowned for creating award-winning educational programs.

26 Oct 2009

Phase 2a clinical trial in nonsense mutation hemophilia A and hemophilia B initiated

PTC Therapeutics, Inc. (PTC) today announced it is expanding the development of ataluren, an investigational new drug, to a third indication with the initiation of a Phase 2a clinical trial in nonsense mutation hemophilia A (nmHA) and hemophilia B (nmHB).

26 Oct 2009

Results from Phase I dose-escalation study of AT-101 announced

Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23, 2009; Abstract # 449).

26 Oct 2009

Anti-viral drug development programs progress successfully, reports NanoViricides

NanoViricides, Inc. (the "Company"), reports that the Company is well financed and its game changing anti-viral drug development programs are progressing successfully. As such, Management knows of no reason for the recent decline in stock price and associated volatility.

26 Oct 2009

Japanese Patent granted for Pharmalink AB's Nefecon

Pharmalink AB announced today that it has been granted Japanese Patent No 4326696, "Methods and means for treating glomerulonephritis" for its product Nefecon(R) which is being developed to treat IgA nephropathy, a glomerulonephritis leading to end-stage renal disease (ESRD). Counterparts of the patent have been issued for other territories including the EU, US and China.

26 Oct 2009

Dextrose solution decreases postoperative nausea and vomiting

A study presented at the 2009 meeting of the American Society of Anesthesiologists seeks to quell a major patient fear when entering the surgical suite - the occurrence of postoperative nausea and vomiting (PONV).

26 Oct 2009

Difficult-to-treat asthma may be attributed to poor medication adherence

Difficult-to-treat asthma often may have more to do with patients who do not take their medication as instructed than ineffective medication, according to researchers in Northern Ireland.

26 Oct 2009

DaVita to demonstrate clinical outcomes, patient care and nutrition through 43 abstracts

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), in conjunction with DaVita Clinical Research®, today announced that company representatives will deliver 43 abstracts—40 posters and three oral presentations—at this year’s American Society of Nephrology’s (ASN) Renal Week to be held in San Diego, Calif., from Oct. 27 – Nov. 1, 2009.

24 Oct 2009

ULURU presents clinical posters; highlights efficacy of Altrazeal dressing for wound care

ULURU Inc. (NYSE Alternext: ULU) today announced that Gregory Bohn, M.D., FACS, Medical Director, Trinity Wound Care and Hyperbaric Medicine, Bettendorf, Iowa, has presented nine clinical posters at the 24th Annual "Clinical Symposium on Advances in Skin and Wound Care" being held in San Antonio, Texas.

24 Oct 2009

FDA issues emergency use authorization for peramivir anti-viral drug

BioCryst Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA), in response to a request from the U.S. Centers for Disease Control and Prevention (CDC), has issued an emergency use authorization (EUA) for the investigational anti-viral drug intravenous (i.v.) peramivir in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza infection who are admitted to a hospital.

24 Oct 2009

Emodin raises hope for treatment of fibrotic liver diseases

In the last decade, advances in the understanding of genes promoting hepatic stellate cell (HSC) activation are impressive. However, there are few breakthroughs in therapeutic intervention of hepatic fibrogenesis. Efficient and well-tolerated antifibrotic drugs are lacking and current treatment of hepatic fibrosis is limited to withdrawal of the noxious agent. Research identifying innocuous antifibrotic agents is of high priority and urgently needed.

24 Oct 2009

FDA issues emergency use authorization for intravenous antiviral drug peramivir in H1N1 patients

The U.S. Food and Drug Administration announced today that, in response to a request from the U.S. Centers for Disease Control and Prevention, it has issued an emergency use authorization (EUA) for the investigational antiviral drug peramivir intravenous (IV) in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza infection who are admitted to a hospital.

24 Oct 2009

Oral News and Research

LX211 may become the first approved oral treatment for modifying the course of uveitis

New data on KAPIDEX for nighttime heartburn in adults with non-erosive GERD presented at the 2009 ACG

Issuance of patents for Idera Pharmaceuticals' TLR-targeted compounds announced

Shire reports results of Lialda and 5-ASA persistency analyses

Protein crucial for insulin regulation may play a role in diabetes

TNF-alpha inhibitors and interleukin inhibitors to drive psoriasis drug market

Oral contraceptives increase stroke risk but benefits still outweigh risks for most users

Inhibikase Therapeutics to illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases

United Treatment Centers announces partnership with Quorum Productions

Phase 2a clinical trial in nonsense mutation hemophilia A and hemophilia B initiated

Results from Phase I dose-escalation study of AT-101 announced

Anti-viral drug development programs progress successfully, reports NanoViricides

Japanese Patent granted for Pharmalink AB's Nefecon

Dextrose solution decreases postoperative nausea and vomiting

Difficult-to-treat asthma may be attributed to poor medication adherence

DaVita to demonstrate clinical outcomes, patient care and nutrition through 43 abstracts

ULURU presents clinical posters; highlights efficacy of Altrazeal dressing for wound care

FDA issues emergency use authorization for peramivir anti-viral drug

Emodin raises hope for treatment of fibrotic liver diseases

FDA issues emergency use authorization for intravenous antiviral drug peramivir in H1N1 patients

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News